TCIM
MLNT

TIAA CREF Investment Management’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

TIAA CREF Investment Management’s Portfolio MLNT Stock Details MLNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$53K Buy
14,873
+7,842
+112% +$42.6K ﹤0.01% 2992
2018
Q4 		$28K Sell
7,031
-11,098
-61% -$142K ﹤0.01% 3003
2018
Q3 		$358K Buy
18,129
+3,472
+24% +$87.8K ﹤0.01% 2833
2018
Q2 		$465K Buy
14,657
+9,838
+204% +$354K ﹤0.01% 2813
2018
Q1 		$178K Sell
4,819
-10,583
-69% -$696K ﹤0.01% 2984
2017
Q4 		$1.22M Buy
+15,402
New +$1.14M ﹤0.01% 2370

Other funds holding MLNT

IP
Isthmus Partners Madison, Wisconsin $1.03B AUM 22.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
ZIM
Zacks Investment Management Chicago, Illinois $12.5B AUM 29.36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TIAA CREF Investment Management's MLNT Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Melinta Therapeutics, Inc. Common Stock (MLNT) stake by 112% in Q1 2019, buying an estimated $42.6K and bringing the position to 14,873 shares worth $53K. The position accounts for ﹤0.01% of the portfolio, ranked #2992.

TIAA CREF Investment Management first reported a position in MLNT in Q4 2017 and has held it in 6 quarters since. The position peaked at $1.22M in Q4 2017. 52 funds tracked by Wall St. Rank hold MLNT as of Q1 2019.

  • TIAA CREF Investment Management held 14,873 shares of Melinta Therapeutics, Inc. Common Stock worth $53K as of Q1 2019.
  • TIAA CREF Investment Management bought 7,842 Melinta Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $42.6K.
  • Melinta Therapeutics, Inc. Common Stock made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2992 holding.
  • TIAA CREF Investment Management first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and has held it in 6 quarters since.
  • TIAA CREF Investment Management's Melinta Therapeutics, Inc. Common Stock position peaked at $1.22M in Q4 2017.
  • 52 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.